Literature DB >> 6537879

Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases.

M C Koppelman, M J Jaffe, K G Rieth, R C Caruso, D L Loriaux.   

Abstract

The syndrome of hyperprolactinemia, galactorrhea, and amenorrhea is frequently caused by a pituitary tumor. Transsphenoidal surgical removal is often advocated for microadenomas, tumors smaller than 10 mm, to prevent the progression of these small adenomas into large tumors. Because no strong evidence indicates that microadenomas naturally progress to macroadenomas, we studied 25 women who had had hyperprolactinemia, amenorrhea, or galactorrhea for a mean duration of 11.3 years. Their mean initial prolactin level was 225 ng/mL (normal, less than 36 ng/mL). Of 22 patients presenting with amenorrhea, 7 resumed menses spontaneously. Galactorrhea resolved completely in 6 of the 19 patients with this disorder. Only 1 patient had progression of a sellar abnormality, and this was slight. Visual fields remained full in all patients, and basal adrenal and thyroid functions remained normal. The mean prolactin level was 155 ng/mL at the reevaluation (p less than 0.01, initial versus reevaluation levels). Hyperprolactinemia apparently has a benign clinical course in most women, and we advocate a conservative approach to management of this disorder.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6537879     DOI: 10.7326/0003-4819-100-1-115

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

Review 1.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 3.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 4.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

5.  Diagnostic value of thyrotropin-releasing-hormone stimulation in patients with pituitary tumor.

Authors:  D M Cook; M A Greer; H Paxton
Journal:  West J Med       Date:  1987-08

6.  Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.

Authors:  Margarida Teixeira; Pedro Souteiro; Davide Carvalho
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 7.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 8.  Managing prolactin-secreting adenomas during pregnancy.

Authors:  Syed Ali Imran; Ehud Ur; David B Clarke
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

9.  Management of prolactinomas in Brazil: an electronic survey.

Authors:  Lucio Vilar; Luciana Ansaneli Naves; Luiz Augusto Casulari; Monalisa Ferreira Azevedo; José Luciano Albuquerque; Fabiano Marcel Serfaty; Flavia R Pinho Barbosa; Antonio Ribeiro de Oliveira; Renan Magalhães Montenegro; Renan Magalhães Montenegro; Alberto José Santos Ramos; Manuel Dos Santos Faria; Nina Rosa C Musolino; Monica R Gadelha; Cesar Luiz Boguszewski; Marcello D Bronstein
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

Review 10.  Pituitary tumors. Current concepts in diagnosis and management.

Authors:  D C Aron; J B Tyrrell; C B Wilson
Journal:  West J Med       Date:  1995-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.